A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid Tumors

Inclusion Criteria: 1. Age between 18 and 75 years inclusive; 2. Histologically or cytologically confirmed advanced malignant solid tumors, eligible patients should be either refractory or intolerant to all available therapies known to confer a clinical benefit as determined by the investigator, except for primary hepatic carcinoma; 3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1; 4. Life expectancy ≥ 3 months; 5. Adequate hematologic, hepatic and renal function; 6. Participant willing to agree to not father a child/become pregnant and comply with effective contraception criteria; 7. Provision of signed and dated, written informed consent prior to any study-specific evaluation. Exclusion Criteria: 1. Previous treatment with any SHP2 inhibitors; 2. Spinal cord compression, meningeal metastases or brain metastases unless asymptomatic, stable and not requiring steroids for at least 2 weeks prior to start of study treatment; 3. Life-threatening autoimmune disease or autoimmune disorder with long-term steroid treatment; 4. Active infection with hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) and treponema pallidum (TP); 5. Patients who have impaired cardiac function or clinically significant cardiac diseases; 6. Active, clinically significant interstitial lung disease or pneumonitis; 7. Females who are pregnant or breastfeeding; 8. Judgment by the investigator that the patient should not participate in the study.